ArticleJournal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract2025
Trends and outcomes for patients receiving neoadjuvant therapy for stage I to III gastric gastrointestinal stromal tumors.
Article in Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
backgroundThe use of neoadjuvant therapy (NAT) is not well characterized across the entire spectrum of localized gastrointestinal stromal tumors (GISTs). This study aimed to identify treatment trends for the use of NAT and survival outcomes in patients who underwent surgery for gastric GISTs.
methodsThe National Cancer Database was queried to identify patients with stage I to III gastric GISTs between 2006 and 2020 who underwent curative-intent surgery after NAT or upfront surgery (UFS). The cohort demographics and cancer characteristics were compared using analysis of variance, generalized linear models, and chi-square analysis. Treatment trends were assessed using linear regression. Cox proportional hazards models and Kaplan-Meier curves were used for propensity score matching (3:1).
resultsBetween 2006 and 2020, 1504 patients (8.1%) received NAT, followed by surgery, and 17,150 patients (91.9%) received UFS with curative intent. The cohort analysis revealed that, compared with patients who underwent UFS, those who underwent NAT had higher grade tumors (P =.031), larger tumors (12.0 vs 6.4 cm, respectively; P <.001), and higher clinical staging (P <.01). Linear regression indicated that the use of NAT became more common each year (0.88%; P <.05) and that NAT was administered for longer durations before surgery (increase in 5.5 d/y; SE, 0.9; P <.05). Despite NAT being used for larger and higher-grade tumors, patients who underwent NAT had similar outcomes as those who underwent UFS (UFS: hazard ratio, 0.86 [95% CI, 0.76-1.01]; P =.07).
conclusionOur results demonstrate that the use of NAT has been increasing over time and that NAT is used for more advanced gastric GISTs. Although NAT is used for higher-risk tumors, its use for gastric GISTs leads to similar outcomes as UFS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.